STOCK TITAN

Arcutis director Howard Welgus proposes $133K share sale

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
144

Rhea-AI Filing Summary

Arcutis Biotherapeutics, Inc. director Howard Welgus reported a proposed sale of 4,728 common shares, with an approximate sale date of November 16, 2026, and an aggregate market value of $133,140.48. The stated Rule 10b5-1 plan adoption or instruction date is March 13, 2026.

The shares listed for sale include 634 shares from restricted-stock vesting on June 4, 2026, and shares from stock-option exercises: 822 acquired November 20, 2019; 1,018 acquired May 31, 2023; and 2,254 acquired June 14, 2024. Welgus also reported sales of 4,730 shares on September 15, 2026, and 4,728 shares on October 15, 2026.

Proposed sale 4,728 common shares Approximate sale date November 16, 2026
Aggregate market value $133,140.48 Shares listed for proposed sale
Shares outstanding 126,455,033 shares Issuer share count stated
Previous sale 4,730 common shares Sold September 15, 2026
Gross proceeds $114,371.40 Sale on September 15, 2026
Previous sale 4,728 common shares Sold October 15, 2026
Gross proceeds $127,325.04 Sale on October 15, 2026
Rule 10b5-1 regulatory
"If Relying on Rule 10b5-1"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
Restricted Stock Vesting financial
"Nature of Acquisition Transaction: Restricted Stock Vesting"
Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.
Stock Option Exercise financial
"Nature of Acquisition Transaction: Stock Option Exercise"
A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ARQT shares did director Howard Welgus propose to sell?

Welgus proposed to sell 4,728 common shares, with an approximate sale date of November 16, 2026, and an aggregate market value of $133,140.48.

What earlier ARQT share sales did Howard Welgus report?

Welgus reported selling 4,730 common shares on September 15, 2026, for gross proceeds of $114,371.40, and 4,728 common shares on October 15, 2026, for gross proceeds of $127,325.04.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading